|
|
|
|
|
Legal status
Patent expired
| (51) | INT.CL. | A61K 31/4184 | (2006.01) |
| C07D 235/04 | (2006.01) | ||
| C07D 235/06 | (2006.01) | ||
| A61P 35/00 | (2006.01) |
| (11) | Number of the document | 2130537 |
| (13) | Kind of document | T |
| (96) | European patent application number | 09011389.5 |
| Date of filing the European patent application | 2003-03-13 | |
| (97) | Date of publication of the European application | 2009-12-09 |
| (45) | Date of publication and mention of the grant of the patent | 2012-11-14 |
| (46) | Date of publication of the claims translation | 2013-02-25 |
| (30) | Number | Date | Country code |
| 364007 P | 2002-03-13 | US |
| (72) |
Wallace, Eli, M., US
Lyssikatos, Joseph, P., US
Hurley, Brian, T., US
Marlow, Allison, L., US
|
| (73) |
Array Biopharma, Inc.,
3200 Walnut Street, Boulder, CO 80301,
US
AstraZeneca AB, 151 85 Södertälje, SE |
| (74) |
Genė Ona SRUOGIENĖ,
UAB TARPINĖ, A.P.Kavoliuko g. 24-152, LT-04328 Vilnius,
LT
|
| (54) | N3 alkilinto benzimidazolo dariniai kaip MEK inhibitoriai |
| N3 alkylated benzimidazole derivatives as mek inhibitors |
| Payment date | Validity (years) | Amount | |
| 2022-03-01 | 347.00 EUR |